Profound Medical Corp
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping… Read more
Profound Medical Corp (PROF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.295x
Based on the latest financial reports, Profound Medical Corp (PROF) has a cash flow conversion efficiency ratio of -0.295x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.48 Million) by net assets ($32.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Profound Medical Corp - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Profound Medical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Profound Medical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Profound Medical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kowloon Development Company Limited
F:KOX
|
0.013x |
|
Changzhou Evergreen Technology Co. Ltd. A
SHE:001324
|
N/A |
|
Zhejiang Bofay Elec Co Ltd
SHE:001255
|
-0.023x |
|
IFE Elevators Co Ltd
SHE:002774
|
0.052x |
|
Quest Holdings S.A
AT:QUEST
|
0.025x |
|
Okea ASA
OL:OKEA
|
5.688x |
|
C.E. Info Systems Limited
NSE:MAPMYINDIA
|
0.009x |
|
Supriya Lifescience Limited
NSE:SUPRIYA
|
0.051x |
Annual Cash Flow Conversion Efficiency for Profound Medical Corp (2014–2024)
The table below shows the annual cash flow conversion efficiency of Profound Medical Corp from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $60.42 Million | $-23.45 Million | -0.388x | +46.39% |
| 2023-12-31 | $31.22 Million | $-22.61 Million | -0.724x | -45.95% |
| 2022-12-31 | $52.00 Million | $-25.80 Million | -0.496x | -78.63% |
| 2021-12-31 | $80.51 Million | $-22.36 Million | -0.278x | -31.42% |
| 2020-12-31 | $97.35 Million | $-20.57 Million | -0.211x | +80.45% |
| 2019-12-31 | $14.29 Million | $-15.45 Million | -1.081x | -57.34% |
| 2018-12-31 | $19.55 Million | $-13.43 Million | -0.687x | +34.59% |
| 2017-12-31 | $11.25 Million | $-11.81 Million | -1.050x | -7.46% |
| 2016-12-31 | $11.04 Million | $-10.79 Million | -0.977x | -98.96% |
| 2015-12-31 | $10.06 Million | $-4.94 Million | -0.491x | +76.65% |
| 2014-12-31 | $1.37 Million | $-2.88 Million | -2.104x | -- |